MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • Various Developments For Oculus Innovative Sciences, Inc. (OCLS) 0 comments
    Jul 3, 2013 3:18 PM | about stocks: OCLS

    Global healthcare company Oculus Innovative Sciences has announced the allowance of a Mexican patent for use of its novel antimicrobial surgical solution in treating and preventing peritonitis. The forthcoming issuance of this patent, which will expire in 2027, will provide More Pharma (Oculus' Latin American partner) with the opportunity to pursue a new drug candidate in Latin America parallel with Ruthigen, Inc.'s (Oculus' subsidiary) development of the drug for the U.S. market. RUT58-60, the novel new formulation, is an advanced next-generation Microcyn Technology drug candidate engineered specifically for use in invasive surgical procedures, including peritonitis.

    An inflammation of the peritoneum, which is the thin tissue lining the inner wall of the abdomen and covering most of the abdominal organs, peritonitis can be either localized or generalized and may result from infection (often because of hollow organ rupture, which can occur in abdominal trauma or appendicitis) or from a noninfectious process.

    Once the Mexican patent has been issued, Oculus' intellectual property estate (either owned or licensed to the company) will include 36 issued patents in the United States and internationally and 109 pending applications - including U.S. provisional applications - directed to chemical compositions, apparatuses, manufacturing methods, and therapeutic uses.

    More Pharma, Oculus' Mexican and Latin American partner, has additionally obtained regulatory approval for marketing the company's Microdacyn60 product family in Honduras. Oculus has separately received approval to launch a new Microcyn-based medical device in Indonesia. The company has also added two new partners in the European Union to sell the Dermacyn family of products in Finland and Serbia.

    For more information, visit www.oculusis.com

    Please see disclaimer on the MissionIR website
    http://www.missionir.com/disclaimer.html

    Stocks: OCLS
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.